|Description||Palbociclib is a potent Cdk4/6 inhibitor.|
|B0084-463335||250 mg||$188||In stock|
|Related CAS||571190-30-2 (Free base); 827022-32-2 (HCl)|
|Synonyms||PD 0332991 Isethionate; PD0332991 Isethionate; PD-0332991 Isethionate; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one isethionate|
BS-181 is a highly selective CDK inhibitor for CDK7 with an IC(50) of 21 nmol/L. Testing of other CDKs as well as another 69 kinases showed that BS-181 only inh...
CDK9-IN-6, one of the CDK9 inhibitors, probably have potential activity in influencing cell cycle of T-type cells.
THZ1-R, with the potential to treat Triple-negative breast cancer (TNBC), it is a potent and selective CDK7 inhibitor but has instability in vivo.
LEE011 is an orally bioavailable and highly specific CDK4/6 (cyclin-dependent kinase 4/6) inhibitor. LEE011 in combination with LGX818 (a V600E BRAF specific in...
THZ2, an analog of THZ1, with the potential to treat Triple-negative breast cancer (TNBC), it is a potent and selective CDK7 inhibitor which overcomes the insta...
CGP 74514 dihydrochloride is a potent and selective cyclin-dependent kinase-1 (Cdk1) inhibitor (IC50 = 25 nM).
R547 is orally bioavailable diaminopyrimidine cyclin-dependent kinase inhibitor (CDKI) with potential antineoplastic activity. CDKI R547 selectively binds to an...
PD 0332991 hydrochloride
PD 0332991 hydrochloride is a cyclin-dependent kinase (CDK) inhibitor with high affinity for CDK4 and CDK6. It has the potential for breast cancer treatment.